Keyphrases
Poor Prognosis
100%
Human Breast Cancer
100%
Programmed Death-ligand 1 (PD-L1)
100%
Programmed Death-ligand 1 Expression
36%
Signaling Pathway
18%
Prognostic Factors
18%
Luminal B
18%
HER2 Subtype
18%
Immunohistochemistry
9%
Clinical Outcomes
9%
Multivariate Analysis
9%
Tissue Microarray
9%
Tumor Cells
9%
Breast Cancer
9%
Basal-like
9%
Primary Tumor
9%
Monoclonal Antibody
9%
Inhibitory Receptors
9%
Tumor Grade
9%
Univariate Analysis
9%
Antibody Targeting
9%
Tumor Size
9%
Breast Cancer Cases
9%
Tumor Immunity
9%
Human Cancer
9%
Ki-67 Expression
9%
Phase 1 Clinical Trial
9%
Epithelial Cancer
9%
Subset Analysis
9%
Tumor Classification
9%
Tumor-infiltrating Lymphocytes
9%
Antibody Therapy
9%
Lymph Node Status
9%
Formalin-fixed
9%
HER2+
9%
ER Expression
9%
Clinical Annotation
9%
Medicine and Dentistry
Breast Cancer
100%
Programmed Death 1 Ligand 1
100%
Programmed Cell Death
27%
Neoplasm
18%
Cancer
18%
Prognostic Factor
18%
Cell Signaling Pathway
18%
Immunohistochemistry
9%
Clinical Trial
9%
Tissue Microarray
9%
Tumor Cell
9%
Primary Tumor
9%
Univariate Analysis
9%
Lymph Node
9%
Multivariate Analysis
9%
Monoclonal Antibody
9%
Programmed Death 1 Receptor
9%
Expression Analysis
9%
Formaldehyde
9%
Tumor Classification
9%
Tumor Infiltrating Lymphocyte
9%
Antibody Therapy
9%
Diseases
9%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Programmed Death 1 Ligand 1
100%
Neoplasm
36%
Programmed Cell Death
27%
Clinical Trial
9%
Primary Tumor
9%
Monoclonal Antibody
9%
Formaldehyde
9%
Programmed Death 1 Receptor
9%
Tumor Classification
9%
Diseases
9%
Biochemistry, Genetics and Molecular Biology
Programmed Cell Death 1
100%
Clinical Trial
25%
Multivariate Analysis
25%
Monoclonal Antibody
25%
Expression Analysis
25%
Tumor Classification
25%
Tissue Microarray
25%
Tumor Volume
25%
Tumor-Infiltrating Lymphocytes
25%
Immunology and Microbiology
Programmed Death 1 Ligand 1
100%
Programmed Cell Death 1
27%
Tumor Cell
9%
Monoclonal Antibody
9%
Lymph Node
9%
Expression Analysis
9%
Tumor Volume
9%
Tumor-Infiltrating Lymphocytes
9%
Programmed Death 1 Receptor
9%
Tumor Classification
9%